Peptide Companion
Peptide Companion
blend
Growth Hormone
Vial: 5mg

How is Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend) dosed and mixed?

Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend) is a peptide blend research reference in the Growth Hormone category for a 5mg vial. The reference mixing guide adds 3 mL of bacteriostatic water, giving a concentration of 3.33 mg/mL. The published research schedule lists 0.2–0.3 mg per injection, 2–3 times daily for 8–12 weeks; it is reference information, not a recommendation.

By Vincent Ceniceros · Published · Last updated

This blend combines tesamorelin, a synthetic GHRH analog, with ipamorelin, a selective ghrelin mimetic (growth hormone secretagogue). When administered together, GHRH analogs and ghrelin mimetics produce synergistic GH pulses. The FDA‑approved tesamorelin dose is 2 mg SC daily, while ipamorelin is commonly studied at 100–300 mcg SC daily. This educational protocol presents a once‑daily subcutaneous approach with gradual titration using a 1:1 blend ratio.

Dose
0.2–0.3 mg per injection
Frequency
2–3 times daily
Timing
Morning, post-workout, before bed
Duration
8–12 weeks

Selective GH secretagogue. Minimal cortisol/prolactin elevation. Excellent safety profile.

Dosing Schedule
WeekTesamorelin DoseIpamorelin DoseUnits (mL)
Weeks 1–2250 mcg (0.25 mg)125 mcg (0.125 mg)23 units (0.23 mL)
Weeks 3–4500 mcg (0.5 mg)250 mcg (0.25 mg)45 units (0.45 mL)
Weeks 5–61000 mcg (1.0 mg)500 mcg (0.5 mg)90 units (0.90 mL)
Weeks 7–101500 mcg (1.5 mg)750 mcg (0.75 mg)135 units (1.35 mL)
Weeks 11–162000 mcg (2.0 mg)1000 mcg (1.0 mg)180 units (1.80 mL)
Mixing & Quick Reference
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
  • •Reconstitute: Add 3.0 mL bacteriostatic water to the 10 mg vial → ~ 3.33 mg/mL total (1.67 mg/mL each peptide).
  • •Typical daily range: 250–2000 mcg tesamorelin + 125–1000 mcg ipamorelin (gradual titration).
  • •Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 16.7 mcg of each peptide on a U‑100 insulin syringe.
  • •Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, use immediately or refrigerate and use within 24–48 hours.
Supplies Needed
  • •Peptide Vials (Tesamorelin 5 mg + Ipamorelin 5 mg, 10 mg blend each):
  • •Insulin Syringes (U‑100):
  • •Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Benefits
  • •Enhanced pulsatile GH secretion through dual‑pathway stimulation.
  • •Tesamorelin (2 mg/day) demonstrated reductions in trunk fat and visceral adipose tissue in HIV‑associated lipodystrophy trials.
  • •Ipamorelin shows high GH selectivity with minimal impact on cortisol or other hormones.
  • •Common adverse events with tesamorelin include injection‑site reactions (erythema, pruritus), arthralgia, and peripheral edema.
  • •Ipamorelin is generally well tolerated; transient flushing or headache may occur.
How It Works

Tesamorelin is a synthetic 44‑amino‑acid GHRH analog that stimulates pituitary GH release. Ipamorelin is a pentapeptide ghrelin mimetic that acts on the GHS‑R1a receptor, selectively stimulating GH secretion without significantly affecting cortisol, prolactin, or ACTH. Combined GHRH + GHRP/ghrelin‑mimetic administration produces synergistic, amplified GH pulses compared to either agent alone. Human pharmacokinetic studies show ipamorelin achieves peak GH release approximately 40 minutes post‑dose.

References and original studies

  • PMC — The Safety and Efficacy of Growth Hormone Secretagogues

    The Safety and Efficacy of Growth Hormone Secretagogues**

    View original study

  • Endocrine Reviews — Growth Hormone Secretagogues

    Growth Hormone Secretagogues**

    View source

  • NCBI LiverTox — Tesamorelin

    Tesamorelin**

    View original study

  • PubMed — Ipamorelin, the first selective growth hormone secretagogue

    Ipamorelin, the first selective growth hormone secretagogue**

    View original study

  • FDA Egrifta (tesamorelin) Label

    SC abdomen injection; rotate sites; storage and reconstitution guidance

    View source

  • CDC — Vaccine Administration: Subcutaneous Injection

    Vaccine Administration: Subcutaneous Injection**

    View source

  • PubMed — Pharmacokinetic-pharmacodynamic modeling of ipamorelin

    Pharmacokinetic-pharmacodynamic modeling of ipamorelin**

    View original study

  • JAMA — Tesamorelin for Abdominal Fat in HIV

    Tesamorelin for Abdominal Fat in HIV**

    View source

  • CDC — Vaccine Administration During

    Vaccine Administration During**

    View source

  • NCBI Bookshelf — Best Practices for Injection

    Best Practices for Injection**

    View original study

  • PMC — Subcutaneous Drug Injection Review

    Subcutaneous Drug Injection Review**

    View original study

About the author

Vincent Ceniceros

Vincent Ceniceros created Peptide Companion and publishes its Dosage Library. Each guide summarizes a reference protocol and links to the studies and sources it draws on.

Published · Last updated

Related guides

Work out the mixing math for any vial with the peptide reconstitution calculator, or browse the full Dosage Library.

Educational content adapted from peptidedosages.com. Not medical advice.